Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
MDT US​

Medtronic Public Limited Company(MDT US)

$95.41-1.181.22%Ext:$95.64+0.230.24%(Market Closed · 23:55:05 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Medtronic Public Limited Company — Company Profile

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Geoffrey Straub Martha
Headquarters
Galway, L2, IE
IPO Date
May 2, 1973
Employees
95,000
Website
www.medtronic.com

Key Metrics

Price
$86.38
Market Cap
$110.57B
Revenue (TTM)
$36.36B
Net Income (TTM)
$4.80B
EPS (TTM)
3.75
P/E (TTM)
21.14
P/B (TTM)
0.00
Dividend Yield
3.26%
ROE (TTM)
2.33%
ROA (TTM)
1.25%
Operating Margin
19.66%
Beta
0.18

Dividends

Last Dividend
$0.71
Last Yield
0.03%

Summary

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Website
www.medtronic.com
Location
Galway, L2, IE
Phone353 1 438 1700
Employees95,000
CEOGeoffrey Straub Martha
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMay 2, 1973

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.3K)

Expand
  • 4Statement of changes in beneficial ownership21 Oct
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)21 Oct
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)21 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers19 Oct
  • 4Statement of changes in beneficial ownership16 Oct
  • 4Statement of changes in beneficial ownership16 Oct
  • SC 13G/AMiniMed Group, Inc.16 Oct
  • 4Statement of changes in beneficial ownership16 Oct
  • 144Marinaro Michael15 Oct
  • 144Martha Geoffrey15 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)14 Oct
  • 425Business combination communication14 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)13 Oct
  • 425Business combination communication13 Oct
  • 425Business combination communication9 Oct
  • 425Business combination communication8 Oct
  • SC TO-I/ATender offer statement (issuer, amendment)8 Oct
  • 425Business combination communication8 Oct
  • 425Business combination communication7 Oct
  • 425Business combination communication7 Oct

EDINET Filings(51)

Expand
  • IRExtraordinary Report8 Sep
  • IRExtraordinary Report8 Sep
  • 10-KAnnual Securities Report (2025.04.26-2026.04.24)20 Aug
  • IRExtraordinary Report20 Aug
  • IRExtraordinary Report20 Aug
  • IRExtraordinary Report19 Apr
  • IRExtraordinary Report19 Apr
  • IRExtraordinary Report13 Mar
  • IRExtraordinary Report23 Jan
  • IRExtraordinary Report23 Jan
  • IRSemi-Annual Report (2025.04.26-2025.10.24)21 Jan
  • IRExtraordinary Report9 Dec 2025
  • IRExtraordinary Report19 Oct 2025
  • IRExtraordinary Report19 Oct 2025
  • IRExtraordinary Report8 Sep 2025
  • IRExtraordinary Report8 Sep 2025
  • 10-KAmended Annual Securities Report26 Aug 2025
  • 10-KAnnual Securities Report (2024.04.27-2025.04.25)25 Aug 2025
  • IRExtraordinary Report18 Jul 2025
  • IRExtraordinary Report18 Jul 2025

News

  • A Look at Medtronic PLC (MDT) After 3.8% Gain -- GF Value $101.17 vs Price $96.5922 Oct
  • Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB22 Oct
  • Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 202622 Oct
  • Arlington Financial Advisors LLC Acquires 9,743 Shares of Medtronic PLC $MDT20 Oct
  • Medtronic (MDT) Stock Dips While Market Gains: Key Facts19 Oct
  • The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning19 Oct
  • First Bank & Trust Buys 10,881 Shares of Medtronic PLC $MDT19 Oct
  • Medtronic (NYSE:MDT) Stock: Insider Geoffrey Martha Sells 50,000 Shares18 Oct
  • How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King?17 Oct
  • Is it Apt to Retain Medtronic Stock in Your Portfolio Now?16 Oct
  • Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable15 Oct
  • Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience15 Oct
  • 3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades15 Oct
  • Medtronic Completes Separation of MiniMed Group, Inc.15 Oct
  • MiniMed Completes Separation from Medtronic15 Oct
  • 7,240 Medtronic PLC $MDT Shares Acquired by Krilogy Financial LLC15 Oct
  • Medtronic Pays More Today. Abbott Raises Its Dividend Faster.14 Oct
  • Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer14 Oct
  • Medtronic PLC $MDT Shares Bought by Allied Investment Advisors LLC14 Oct
  • Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know13 Oct

Mentions in Filings

  • … used in patients with motor fluctuations despite optimization of L‑dopa, including DBS devices such as Infinity and Liberta RC (both marketed by Abbott), Vercise (marketed by Boston Scientific), and Percept (marketed by <strong>Medtronic</strong>), as well as Focused Ultrasound (FUS) technologies such as Exablate Neuro (marketed by Insightec). We anticipate that there will continue to be improvements in DBS and FUS technologies. We are aware of cell and gene ther …
    Aspen Neuroscience, Inc.Medtronic Public Limited Company·S-1/A - Registration statement (general form, amendment)·Q4 26·22 Oct
  • … o, the following: Beijing Surgerii Robotics Company Limited; CMR Surgical Ltd.; Distalmotion SA; Harbin Sizhe Rui Intelligent Medical Equipment Co., Ltd.; Johnson & Johnson; Karl Storz SE & Co. KG; Medicaroid Corporation; <strong>Medtronic plc</strong>; meerecompany Inc.; Noah Medical Corporation; Shandong Weigao Group Medical Polymer Company Ltd.; Shanghai Microport Medbot (Group) Co., Ltd.; Shenzhen Edge Medical Co., Ltd.; and SS Innovations International, Inc.
    INTUITIVE SURGICAL INCMedtronic Public Limited Company·10-Q - Quarterly report Q3·Q3 26·21 Oct
  • … nt of Global Marketing of Reliant Technologies, a venture-backed aesthetic medicine company, from April 2006 to August 2008. From April 2004 to April 2006, Ms. Krammer served as Senior Director of Strategic Marketing of <strong>Medtronic</strong> Corporation. From December 2000 to September 2001, Ms. Krammer served as Vice President, Solutions Marketing of Getronics Corporation, a global IT services company. From April 1999 to December 2000, Ms. Krammer served as …
    Vivos Therapeutics, Inc.Medtronic Public Limited Company·PRER14A - Preliminary proxy statement (revision)·Q4 26·21 Oct
  • … nt of Global Marketing of Reliant Technologies, a venture-backed aesthetic medicine company, from April 2006 to August 2008. From April 2004 to April 2006, Ms. Krammer served as Senior Director of Strategic Marketing of <strong>Medtronic</strong> Corporation. From December 2000 to September 2001, Ms. Krammer served as Vice President, Solutions Marketing of Getronics Corporation, a global IT services company. From April 1999 to December 2000, Ms. Krammer served as …
    Vivos Therapeutics, Inc.Medtronic Public Limited Company·PRE 14A - Preliminary proxy statement·Q4 26·19 Oct
  • Pharmaceuticals (NASDAQ: TARS), Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi-I-Ko), China Kanghui (NYSE:KH, acquired by <strong>Medtronic</strong>), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), NKF Pharma (SHA: 603707), Pathalys Pharma, Inc. (since August 2024), LB Pharma (from November 2023 to September 2025), Artios Pharma Ltd. (from July 2021 to September 20 …
    TCGX Acquisition Corp. IIMedtronic Public Limited Company·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·16 Oct
  • … the Company’s Registration Statement on Form S-1, as amended (File No. 333-286295), filed with the SEC on August 6, 2025). | | 10.51 | Security Agreement, dated July 27, 2023, by and between SynCardia Systems, Inc. and <strong>Medtronic</strong>, Inc. (incorporated by reference to Exhibit 10.50 to the Company’s Registration Statement on Form S-1, as amended (File No. 333-286295), filed with the SEC on August 6, 2025). | | 10.52 | Non-Exclusive License Agreement, …
    Picard Medical, Inc.Medtronic Public Limited Company·S-3 - Registration statement (primary offering)·Q4 26·22 Oct

Key Stats

Trading

Px/Chg 1D$86.38 / -0.07%
Avg Volume9.56M
Beta0.18
Mkt Cap110.57B
FD Mkt Cap116.17B

Float

Shrs Out/Float1.28B / 1.28B
Short Float0.01%
Days to Cover1.73
Stock Repurchased$1.03B

Current Valuation

EV108.78B
EV/EBITDA11.51
EV/Sales2.90
P/B0.00
P/S2.95
FCF Yield1.17%
ROE2.33%
ROA1.25%
Current Ratio2.54

Dividend

Cash$0.71
Yield3.26%
Yield (TTM)3.26%

Estimates

P/E21.14
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgAug '23Aug '24Aug '25Aug '26Oct '26
PRICE-BASED RATIOS
Price / Earnings68.3229.1332.27111.6693.3575.22
Price / Sales8.713.513.6713.2211.8311.33
Price / Book Value1.862.132.362.462.370.00
Price / Free Cash Flow49.0223.9022.8157.0455.6585.71
ENTERPRISE VALUE METRICS
Enterprise Value134,304.7132,458.8142,562.7144,552.9143,171.5108,777.7
Enterprise Value / Sales10.124.244.4016.1914.6011.15
Enterprise Value / EBITDA41.2215.2317.3863.5454.2955.64
Enterprise Value / EBIT55.0522.0825.66100.7371.1655.64

Financials

Full Financials
Millions USD5Yr CAGR (%)Apr '22Apr '23Apr '24Apr '25Apr '26
INCOME STATEMENT
Revenue3.5%31,686.031,227.032,364.033,537.036,364.0
Gross Income2.4%21,541.020,508.021,148.021,905.023,643.0
EBITDA2.8%8,777.08,697.08,203.09,218.09,809.0
EBIT3.1%6,070.06,000.05,556.06,357.06,851.0
Net Income-1.2%5,039.03,758.03,676.04,662.04,800.0
EPS (Diluted)0%3.732.822.763.613.73
BALANCE SHEET
Cash & ST Inv-5.4%10,573.07,959.08,005.08,965.0—
Total Assets25.5%90,981.090,948.089,981.091,680.0—
Total Liabilities4.3%38,259.039,283.039,561.043,424.0—
Total Shareholder Equity-3%52,551.051,483.050,214.048,024.0—
CASH FLOW
Net Operating Cash Flow-5.4%7,346.06,039.06,787.07,044.07,330.0
Cap Ex8.6%-1,368.0-1,459.0-1,587.0-1,859.0-1,904.0
Free Cash Flow-2.4%5,978.04,580.05,200.05,185.05,426.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)95.72
Basic Shares1,280.05
Market Cap122,526.4
Diluted Shares1,285.10
Fully Diluted Shares Outstanding1,285.10
Fully Diluted Market Cap123,009.8
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,793.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value120,733.4

Segment data

Revenue

by Products and services

  • Cardiac And Vascular Group39%
  • Neuroscience Group28%
  • Medical Surgical24%
  • Diabetes Group9%

Revenue

by Geography

  • United States80%
  • Total Other Countries, Excluding United States And Ireland20%
  • Ireland0%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US